Search results
Raleigh Capital Management Inc. Has $2.67 Million Position in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 4 days agoRaleigh Capital Management Inc. grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.9% during the 4th quarter, according to the company in its most recent disclosure ...
Security National Bank of SO Dak Purchases 102 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 6 days agoSecurity National Bank of SO Dak lifted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.6% during the 4th quarter, according to the company in its most recent Form ...
CCM Investment Advisers LLC Trims Stock Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 3 days agoCCM Investment Advisers LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.1% during the 4th quarter, according to the company in its most recent Form ...
Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
Benzinga via Yahoo Finance· 6 days agoWith 52 consecutive years of dividend growth and a dividend yield of over 3.6%, AbbVie Inc....
Brevan Howard Capital Management LP Makes New $1.97 Million Investment in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 6 days agoBrevan Howard Capital Management LP purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, Holdings Channel reports. The fund purchased ...
AbbVie joins in latest gastrointestinal drug chase
BioPharma Dive via Yahoo Finance· 6 days agoAbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate...
AbbVie and FutureGen link on inflammatory bowel disease
Pharmaceutical Technology via Yahoo Finance· 6 days agoAbbVie has made a licence agreement with FutureGen Biopharmaceutical to develop a next-generation...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
FOX 23 News Albany· 1 day agoFood and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL...
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis
Market Watch· 1 day agoPublished: June 18, 2024 at 6:36 p.m. ETShareResizeBy Sabela OjeaAbout Dow Jones NewswiresDow Jones Newswires is a market-moving financial and business news source, used by wealth managers, ...
AbbVie inks immune disorder drug licensing deal with China's FutureGen
Reuters via AOL· 7 days agoAbbVie has been counting on its newer immunology medicines to help make up for declining sales of...